Verrica Pharma To Present Phase 2 Clinical Data Highlighting Potential Abscopal Effects Of Oncolytic Peptide, VP-315, In Treatment Of Basal Cell Carcinoma At 2026 SID Annual Meeting

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors 

WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois. Patients with BCC frequently present with multiple tumors, and approximately one-third will develop additional primary tumors over their lifetime, highlighting the need for therapies that address diseases such as BCC with multifocal potential.